Tenofovir/Levonorgestrel Intravaginal Ring and Tenofovir Intravaginal Ring

PHASE2UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 12, 2018

Primary Completion Date

August 20, 2019

Study Completion Date

April 30, 2020

Conditions
HIVContraceptionPreventionAnti-Retroviral Agent
Interventions
DRUG

TFV/LNG IVR

TFV/LNG IVR is an intravaginal ring that releases approximately 8-10 mg/day of TFV and approximately 20ug/day of LNG to be used for 90 continuous days.

DRUG

TFV IVR

TFV IVR is an intravaginal ring that releases approximately 8-10mg/day of TFV to be used for 90 continuous days.

DRUG

Placebo IVR

Placebo IVR is an intravaginal ring containing no active experimental ingredients to be used for 90 continuous days.

Trial Locations (1)

40100

Kenya Medical Research Institute, Center for Global Health Research, Kisumu

Sponsors
All Listed Sponsors
collaborator

Kenya Medical Research Institute

OTHER

collaborator

University of Washington

OTHER

collaborator

Centers for Disease Control and Prevention

FED

lead

CONRAD

OTHER